DRI entered into a purchase agreement with an affiliate of Radius Health, a Boston-based biopharmaceutical company focused on bone health, for an upfront purchase price of $130 million.
The post DRI to acquire second royalty interest in Orserdu drug sales appeared first on PE Hub.
Powered by WPeMatico
Source: https://www.pehub.com/dri-to-acquire-second-royalty-interest-in-orserdu-drug-sales/
Comments are closed.